IL13 and bronchiectasis: A Greek study noted that 17.5% of patients with bronchiectasis might have an eosinophilic phenotype (defined as the presence of more than 3% sputum eosinophil at stable state) which was associated with higher levels of fractional exhaled nitric oxide (FeNO), greater bronchodilator reversibility in forced expiratory volume in 1 second (FEV1) and higher sputum IL‐13 levels.18